KBI Biopharma and Selexis Hold Joint Ribbon Cutting of the Expanded State-of-the-Art Facility in Geneva, Switzerland
Read MoreWith unparalleled proprietary technology and highly specialized expertise that can translate scientific innovation into life-saving medicines, Selexis is a leading provider of cell line expression technologies that are vital to the discovery and development of therapeutic proteins. Bolstered by our novel, proprietary SUREtechnology Platform™, we have the capabilities to facilitate the rapid, stable, safe, and cost-effective production of virtually any recombinant protein. Our combination of proprietary technology and unparalleled expertise provides seamless integration of the bioproduction continuum, spanning discovery to commercialization.